Histone deacetylase inhibitors for treatment of hepatocellular carcinoma
Authors:
- 1 September 2005
- journal article
- review article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 26 (9) , 1025-1033
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Surgical resection has been considered the optimal treatment approach, but only a small proportion of patients are suitable candidates for surgery, and the relapse rate is high. Approaches to prevent recurrence, including chemoembolization before and adjuvant therapy after surgery, have proven to have a limited benefit; liver transplantation is successful in treating limited-stage HCC because only a minority of patients qualify for transplantation. Therefore, new therapeutic strategies are urgently needed. Because in addition to the classical genetic mechanisms of deletion or inactivating point mutations, epigenetic alterations, such as hyperacetylation of the chromatin-associated histones (responsible for gene silencing), are believed to be involved in the development and progression of HCC, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In particular, pre-clinical results obtained using HA-But, an HDAC inhibitor in which butyric acid residues are esterified to a hyaluronic acid backbone and characterized by a high affinity for the membrane receptor CD44, indicated that this class of compounds may represent a promising approach for hepatocellular carcinoma treatment.Keywords
This publication has 67 references indexed in Scilit:
- Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cellsJournal of Hepatology, 2004
- A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogenGene Therapy, 2002
- Translating the Histone CodeScience, 2001
- The Hallmarks of CancerCell, 2000
- Genetic Aspects of Hepatocellular CarcinogenesisSeminars in Liver Disease, 1999
- Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?European Journal of Cancer, 1998
- Recurrence of hepatocellular carcinoma after surgeryBritish Journal of Surgery, 1996
- Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinomaEuropean Journal of Cancer, 1994
- Degradation and intracellular accumulation of a residualizing hyaluronan derivative by liver endothelial cellsHepatology, 1993
- Clinical pharmacology of sodium butyrate in patients with acute leukemiaEuropean Journal of Cancer and Clinical Oncology, 1987